Terremoto Biosciences is a privately held, clinical-stage biotechnology company based in South San Francisco, California, building a covalent drug discovery and development engine around lysine-based covalency. Founded in 2022 by veterans of Principia Biopharma and backed by OrbiMed and Third Rock Ventures across Series A ($75M), Series B ($175M) and Series C ($108M) financings, the company designs highly selective small-molecule medicines aimed both at improving on known drug targets and at reaching targets previously considered undruggable. Its lead program, TER-2013, is an AKT1-selective inhibitor granted FDA Fast Track designation for breast cancer, with additional work in oncology and hereditary hemorrhagic telangiectasia. Terremoto is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable API contract, and its public web surface is a corporate marketing site covering science, pipeline, news and careers.
Terremoto Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Life Sciences.
Terremoto Biosciences’ developer surface includes engineering blog, support, and 6 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/terremoto-biosciences/"><img src="https://apis.io/badge/terremoto-biosciences/card.svg" alt="Terremoto Biosciences on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
aid: terremoto-biosciences
name: Terremoto Biosciences
description: 'Terremoto Biosciences is a privately held, clinical-stage biotechnology company based in South San Francisco,
California, building a covalent drug discovery and development engine around lysine-based covalency. Founded in 2022 by
veterans of Principia Biopharma and backed by OrbiMed and Third Rock Ventures across Series A ($75M), Series B ($175M) and
Series C ($108M) financings, the company designs highly selective small-molecule medicines aimed both at improving on known
drug targets and at reaching targets previously considered undruggable. Its lead program, TER-2013, is an AKT1-selective
inhibitor granted FDA Fast Track designation for breast cancer, with additional work in oncology and hereditary hemorrhagic
telangiectasia. Terremoto is a therapeutics developer, not a software vendor: it publishes no public API, developer portal,
SDK or machine-readable API contract, and its public web surface is a corporate marketing site covering science, pipeline,
news and careers.'
url: https://raw.githubusercontent.com/api-evangelist/terremoto-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
probe_state: none
source:
- security
generated: '2026-11-06'
method: derived
specificationVersion: '0.20'
created: '2026-08-30'
modified: '2026-08-30'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Oncology
- Healthcare
- Clinical Stage
- Small Molecule
image: https://terremotobio.com/wp-content/uploads/Terremoto_Footer_Logo.png
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/terremoto-biosciences-domain-security.yml
- type: LLMsTxt
url: llms/terremoto-biosciences-llms.txt
- type: Website
url: https://terremotobio.com/
- type: About
url: https://terremotobio.com/about/
- type: Blog
url: https://terremotobio.com/news/
- type: Support
url: https://terremotobio.com/contact/
- type: TermsOfService
url: https://terremotobio.com/terms-of-use/
- type: PrivacyPolicy
url: https://terremotobio.com/privacy/privacy-policy/
x-enrichment:
date: '2026-08-30'
status: minimal
artifacts_added: 3
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Terremoto Biosciences is a clinical-stage covalent small-molecule drug developer whose entire public surface is
a WordPress marketing site (science, pipeline, news, careers) — every contract probe missed (no OpenAPI/Swagger at the
root, no /graphql, no /mcp, no agent card, and none of api./developers./docs./portal.terremotobio.com resolve in DNS),
leaving only the WordPress CMS's own incidental /wp-json/ route index and an All in One SEO-generated llms.txt, neither
of which is a product API.
evidence:
- url: https://terremotobio.com/openapi.json
status: 404
- url: https://terremotobio.com/graphql
status: 404
- url: https://terremotobio.com/.well-known/agent-card.json
status: 404
- url: https://api.terremotobio.com/
status: 0
- url: https://terremotobio.com/llms.txt
status: 200
- url: https://terremotobio.com/wp-json/
status: 200
checked: '2026-08-30'
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.